Bolt Biotherapeutics Inc(BOLT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -16.44 | Insider Own | 14.93% | Shs Outstand | 1.9M | Perf Week | 47.8% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | -10.51% | Insider Trans | -11.52% | Shs Float | 1.6M | Perf Month | 84.1% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | -3.69 | Inst Own | 18.17% | Short Float | 0.96% | Perf Quarter | 65.45% |
| Income | -0.03B | P/S | 2.61 | EPS this Y | -2.35% | Inst Trans | -2.31% | Short Ratio | 0.07 | Perf Half Y | 31.61% |
| Sales | 0.00B | P/B | 0.97 | EPS next 5Y | -19.99% | ROA | -49.62% | Short Interest | 0.02M | Perf YTD | 16.5% |
| Book/sh | 6.56 | P/C | 0.69 | EPS past 3/5Y | 27.67% 11.84% | ROE | -111.65% | 52W High | -18.12% ($7.78) | Perf Year | 2.08% |
| Cash/sh | 9.24 | P/FCF | - | Sales past 3/5Y | 10.33% 101.61% | ROIC | -92.19% | 52W Low | 105.48% ($3.10) | Perf 3Y | -66.48% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 37.93% | Gross Margin | 80.45% | Volatility(W/M) | 12.51% 9.66% | Perf 5Y | -97.41% |
| Dividend TTM | - | EV/Sales | 3.42 | Sales Y/Y TTM | 12.79% | Oper. Margin | -605.85% | ATR (14) | 0.58 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.61 | EPS Q/Q | -2.29% | Profit Margin | -611.47% | RSI (14) | 76.8 | Recom | 1.67 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.61 | Sales Q/Q | -99.72% | SMA20 | 48.72% ($4.28) | Beta | 0.95 | Target Price | $48.5 |
| Payout | - | Debt/Eq | 1.71 | Earnings | 2026/8/11 | SMA50 | 61.74% ($3.94) | Rel Volume | 0.77 | Prev Close | $6.59 |
| Employees | 23 | LT Debt/Eq | 1.47 | EPS/Sales Surpr. | -34.94% -99% | SMA200 | 41.52% ($4.5) | Avg Volume(3M) | 0.23M | Price | $6.37 |
| IPO | 2021/2/5 | Option/Short | No/Yes | Trades | 978 | Volume | 177,813 | Change | -3.34% |
🧬 A clinical-stage biotech company developing immune-based anticancer therapeutics, including immune-stimulating antibody-drug conjugates (ISACs) and macrophage-activating antibodies. Its lead pipeline includes BDC-3042, a dectin-2 agonist (Phase 1 completed), and BDC-4182, a next-generation ISAC targeting claudin 18.2 (Phase 1 ongoing), alongside global co-development agreements with partners such as Genmab and Toray.
Over the past 1 year, roughly in the middle
18% below its 1-year high.
Traded less than usual. That is 77% of its average volume.
BOLT has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -2.4% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $261. Peers typically go for $1,034.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -97.4%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 18.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #486 of 594 in the industry
Based on market cap of $12M.
AEON#484 AEON Biopharma Inc $12M PER - 
BIVI#485 BioVie Inc $12M PER - BOLT#486 Bolt Biotherapeutics Inc $12M PER - 
ATYR#487 Atyr Pharma Inc $12M PER - 
LPCN#488 Lipocine Inc $12M PER - 
FAQ
What kind of company is BOLT?
BOLT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of BOLT?
The market cap of BOLT is approximately $12M, ranking 5,373 within its sector.
What is the 52-week high and low for BOLT?
BOLT has recorded a 52-week high of $7.78 and a low of $3.10.
